Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by MRP Capital Investments LLC

MRP Capital Investments LLC decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,680 shares of the pharmaceutical company’s stock after selling 345 shares during the quarter. Vertex Pharmaceuticals comprises about 1.6% of MRP Capital Investments LLC’s investment portfolio, making the stock its 17th largest holding. MRP Capital Investments LLC’s holdings in Vertex Pharmaceuticals were worth $1,725,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of VRTX. Capital World Investors grew its position in Vertex Pharmaceuticals by 21.3% in the 4th quarter. Capital World Investors now owns 21,805,770 shares of the pharmaceutical company’s stock worth $8,872,586,000 after purchasing an additional 3,824,103 shares during the last quarter. Capital Research Global Investors boosted its position in shares of Vertex Pharmaceuticals by 61.0% during the first quarter. Capital Research Global Investors now owns 5,743,882 shares of the pharmaceutical company’s stock worth $2,401,000,000 after buying an additional 2,176,218 shares during the period. Jennison Associates LLC boosted its position in shares of Vertex Pharmaceuticals by 21.2% during the first quarter. Jennison Associates LLC now owns 4,782,374 shares of the pharmaceutical company’s stock worth $1,999,080,000 after buying an additional 837,461 shares during the period. Swedbank AB bought a new position in Vertex Pharmaceuticals in the 1st quarter worth approximately $277,317,000. Finally, AMF Tjanstepension AB acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at approximately $257,655,000. Institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total transaction of $2,689,860.00. Following the completion of the sale, the director now owns 40,000 shares of the company’s stock, valued at approximately $20,320,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 15,202 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $497.00, for a total value of $7,555,394.00. Following the completion of the sale, the chief executive officer now directly owns 106,172 shares of the company’s stock, valued at $52,767,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce I. Sachs sold 5,295 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $508.00, for a total transaction of $2,689,860.00. Following the transaction, the director now owns 40,000 shares in the company, valued at approximately $20,320,000. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,047 shares of company stock worth $16,843,806. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $474.16 on Thursday. Vertex Pharmaceuticals Incorporated has a 12 month low of $341.85 and a 12 month high of $510.64. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02. The stock has a market cap of $122.38 billion, a PE ratio of 30.77 and a beta of 0.40. The business has a fifty day simple moving average of $483.42 and a 200-day simple moving average of $451.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). The business had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The company’s revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.53 earnings per share. On average, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on VRTX. TD Cowen boosted their price target on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Royal Bank of Canada reduced their price objective on shares of Vertex Pharmaceuticals from $424.00 to $421.00 and set a “sector perform” rating for the company in a report on Tuesday, June 11th. Guggenheim raised their target price on shares of Vertex Pharmaceuticals from $450.00 to $558.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Redburn Atlantic initiated coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, June 27th. They set a “buy” rating and a $545.00 price target on the stock. Finally, BMO Capital Markets increased their price objective on shares of Vertex Pharmaceuticals from $480.00 to $500.00 and gave the company an “outperform” rating in a report on Friday, May 31st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $485.91.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.